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The cell cycle regulators involved in maintaining the quiescence, and thereby the self-renewal capacity, of
somatic stem cells have long been elusive. Two new Cell Stem Cell articles in this issue (Matsumoto et al.,
2011; Zou et al., 2011) now show that the CDK inhibitor p57 is a crucial brake for cycling HSCs, and links
self-renewal activity to cell cycle quiescence.The self-renewal activity of somatic stem cells often inversely
correlates with cell cycle activity. This pattern has been shown
for epidermal, muscle, and adult neuronal stem cells and has
probably been the most extensively studied in bone marrow
hematopoietic stemcells (HSCs) (Wilson et al., 2008). In a healthy
adult mouse, the most potent HSCs are in a deep dormancy
phase, a status in which the metabolism and S phase machinery
are mostly downregulated. Mathematical modeling combined
with functional assays suggests that dormant HSCs divide about
five times per lifetime. While dormant HSCs form a silent reser-
voir of stem cells during homeostasis, they are efficiently acti-
vated to proliferate and self-renew in response to stress and
injury signals such as lypopholisaccharides or alpha and gamma
type interferons produced during bacterial or viral infections
(Essers et al., 2009; King et al., 2011; Takizawa et al., 2011; Wil-
son et al., 2008). Extrapolation of the cycling kinetics of dormant
mouse HSCs to humans would indicate that some human HSCs
would only divide about once every 18 years. However, in
contrast to laboratory mice that are kept under semisterile,
specific pathogen free (SPF) conditions, humans are constantly
exposed to bacterial and viral infections; thus, at least part of the
HSC pool is most likely persistently activated, making it unlikely
that long-term dormant cells exist in humans. Nevertheless,
in vivo clonal analysis of human HSCs revealed cell cycle
dynamics similar to those observed in mice, as it was shown
that HSCs can become quiescent for months followed by
another productive cycling phase (McKenzie et al., 2006). More-
over, the biological state of dormancy is certainly critical for
the maintenance of high self-renewal capacity, which simulta-
neously makes HSCs insensitive to antiproliferative chemother-
apeutic drugs. Typically, proliferation-inducing cytokines or
genetic mutations that decrease quiescence and induce HSC
cycling almost always result in exhaustion of the HSC pool,
and do so in transplantation settings in particular (Wilson et al.,
2009). It is widely assumed that signals from the bone marrow
stem cell niches control the balance between HSC dormancy
and self-renewal (Ehninger and Trumpp, 2011). One of the quies-
cence-inducing pathways initiated by niche cells is the THPO-
cMPL pathway, which later on during ontogeny is also involved
in differentiation of themegakaryocytic lineage. The link between
this pathway and the cell cycle machinery of HSCs appeared to
be at least in part mediated by regulating Cyclin-Dependent
Kinase (CDK) inhibitors (CDKis) such as p57KIP2 (p57) (Yoshi-hara et al., 2007). Although p57 expression is known to correlate
with quiescence and self-renewal status, functional proof that
p57 actively participates in maintaining or inducing HSC quies-
cence has not been reported. In this issue of Cell Stem Cell,
two studies genetically dissect the role of p57 in HSC function
and address its impact on cell cycle control and self-renewal
(Matsumoto et al., 2011; Zou et al., 2011).
The G1 Phase of the Cell Cycle
Within the four phases (G1/S/G2/M) of the cell division cycle, it is
only in G1 phase where the decision to cycle is dependent on
external stimuli. Progression to S phase and proliferation only
occurs in the presence of growth factors, while in their absence,
cells enter a quiescent G0 phase. The G1 phase is separated into
an early and late G1 phase by the ‘‘restriction point’’ or ‘‘G1/S
checkpoint.’’ If cells pass this point, they are committed to
continue through an entire cycle and no longer require growth
factors to complete division (Figure 1A).
The early and late G1 phases are controlled by enzymatic
complexes formed by CDKs and their associated cyclins.
During the early G1 phase, mitogenic stimulation promotes ex-
pression of D-type cyclins that associate with CDK4 or CDK6.
CyclinD-CDK4 and cyclinD-CDK6 complexes phosphorylate
the transcriptional repressor Retinoblastoma (Rb), resulting in
its inactivation (Figure 1A). Phosphorylated Rb no longer inhibits
the E2F transcription factors that activate a complex program
promoting S phase initiation and progression. The initial inacti-
vating Rb phosphorylation corresponds to transition through
the restriction point and progression to late G1 phase. In this
phase, induction of cyclinE promotes activation of cyclinE-
CDK2 complexes, which hyperphosphorylates Rb and leads
to further activation of S phase genes (Sherr and Roberts,
1999) (Figure 1A).
An additional level of complexity is added by the presence of
CDKis, which reversibly antagonize cell cycle progression.
CDKis are classified into two families. The INK4 family com-
prising p16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4 targets
CDK4 or CDK6. The CDKis p21, p27, and p57 belong to the
Cip/Kip family that exhibits a broader spectrum by inhibiting
also CDK2 on top of CDK4 and CDK6 (Figure 1A). Interestingly,
p21 and p27 can also facilitate the activation of cyclinD-CDKs
(Sherr and Roberts, 1999). Moreover, in contrast to INK4, the
Cip/Kip family mediates cell cycle-independent functions byCell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc. 187
Figure 1. Function and Expression of CDK Inhibitors
(A) In the early G1 phase, activation of cyclinD-CDK4/6 promotes Rb phosphorylation. This step is targeted by both INK4 and Cip/Kip family members. In late G1
phase, Rb hyperphosphorylation by cyclinE-CDK2 complexes facilitates transition to S phase. Components of the Cip/Kip family inhibit both cyclinE-CDK2 in late
G1 phase and cyclinA-CDK2 at the beginning of S phase.
(B) Overview of the mRNA expression levels of INK4 and Cip/Kip family members in long-term HSCs, short-term HSCs, and multipotent progenitors, as well as
compensatory mechanisms occurring in the constitutive (p57KO) or conditional (p57DMx) absence of p57.
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regulation of Rho activity (Besson et al., 2004).
p57, a CDKi Important for Development and Cancer
The apparently inverse relationship between cell cycle activity
and self-renewal capacity in HSCs puts CDKis at the heart of
the pool of candidates that induce quiescence and possibly
preserve self-renewal. Indeed, in various previous studies, high
expression of p57 was observed in normal mouse HSCs. In
more general terms, expression of p57 is highly restricted in adult
tissues, but is expressed during fetal organogenesis, particularly
in differentiating cells. Mice lacking p57 show perinatal lethality
and display a large number of developmental defects. Interest-
ingly, these defects are strikingly similar to those observed in
Beckwith-Wiedemann syndrome patients, and various studies
demonstrate direct involvement of the p57 locus in the patho-
genesis of this syndrome (Pateras et al., 2009; Zhang et al.,
1997) Moreover, transcriptional and translational downregula-
tion of p57 is frequent in many human cancers, including
lymphoid malignancies, strongly suggesting that this protein
has tumor-suppressing-like effects in various cancers (Pateras
et al., 2009).
p57 Is Highly Expressed and Required for HSC
Quiescence
p57 transcripts and protein are highly expressed in primitive,
quiescent HSCs, defined phenotypically by the expression of
Sca1 and cKit, and by the absence of CD34 and Lineagemarkers
(CD34-LSK). This expression progressively declines during dif-
ferentiation toward less self-renewing multipotent progenitors
(Figure 1B) (Passegue´ et al., 2005; Yamazaki et al., 2006,
2009). It is thought that dormant/quiescent HSCs are maintained
in specialized niches that provide signals that maintain their stem
cell fate (Ehninger and Trumpp, 2011). These signals include188 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.TPO and TGF-beta, both of which increase p57 expression,
thus linking p57 function to niche-mediated maintenance of
functional HSCs (Yamazaki et al., 2006; Yoshihara et al., 2007).
Although these previous studies hypothesized a critical role for
p57 in regulating HSC quiescence and self-renewal, genetic
data on the function of this CDKi in HSCs were still missing. In
this issue of Cell Stem Cell, the groups of Toshio Suda and Keii-
chi Nakayama provide new insights into this topic by analyzing
HSCs lacking p57 (Matsumoto et al., 2011; Zou et al., 2011).
In the first manuscript, Matsumoto and colleagues circum-
vented the perinatal lethality of p57/ mice by generating a
conditional p57flox allele, which in combination with the MxCre
transgene can be inducibly deleted in the entire hematopoietic
system by treatment with poly(I)-poly(C) (pIC). Four weeks after
deletion of p57, mutant mice showed a 2-fold reduction in hema-
topoietic progenitors (CD34+LSK, CD150+CD48-LSK) and in
primitive CD34-LSK HSCs, highly enriched in functional HSCs.
This phenotype was associated with an equivalent decrease in
quiescent cells. In addition, p57-deficient stem/progenitors
showed a 2-fold increase in p53-mediated apoptosis. At a func-
tional level, mutant HSCs showed a 5-fold reduction in their
capacity to reconstitute lethally irradiated recipients, which
further decreased in secondary transplants. Interestingly, HSC
repopulating capacity was intrinsically affected by p57 defi-
ciency, since pIC-mediated deletion of p57 in mice previously
reconstituted with a 1:1 mixture of undeleted MxCre;p57flox/flox
and control BM cells resulted in the robust decrease of mutant
HSCs over time (Matsumoto et al., 2011). The dependency
of HSCs on p57 was specific to this CDKi because mutants
for the other two CIP/KIP members, p21 and p27, did not
show defective repopulating potential, confirming earlier reports
(Cheng et al., 2000; van Os et al., 2007).
The authors also addressed the question of redundancy and
analyzed HSCs lacking both p57 and p21. While the double
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in vivo, the colony-forming capacity was strongly reduced in
double mutant cells, suggesting that p21 is an important regu-
lator in culture stress-induced cell activity, but is likely not
involved in normal HSC function. Finally, the authors wondered
whether the specific role of p57 is indeed due to its specific bio-
logical activity compared with the other CDKIs. To address this
point, they analyzed HSCs from a knockin (KI) mouse line in
which the p57 coding region was replaced by that for p27. Strik-
ingly, expression of four alleles of p27 (two endogenous and two
from the p57 locus) generated normal HSCs even in the absence
of any p57 protein (Matsumoto et al., 2011). This suggests that
the two proteins are highly similar with respect to their biological
activity, and that the importance of p57 in HSCs is rather due to
its specific expression pattern, i.e., p57 being highly expressed
in quiescent/dormant HSCs but downregulated in progenitors.
In the second report, Zou et al. circumvent the newborn
lethality of p57/ mice by transplanting mutant fetal liver (FL)
HSCs into lethally irradiated adult recipients and compared their
repopulation activity to that of wild-type FL cells. While p57/
FL HSCs could normally reconstitute adult hematopoiesis in
primary and secondary transplants, they showed a 2-fold
impaired repopulating capacity in tertiary recipients. This rela-
tively subtle self-renewal deficiency was not associated with
alteration of HSC quiescence. As it seemed likely that other
CDKi factors compensate for p57 deficiency in the mutant
FL-donor-derived HSCs, the authors determined the expression
of p18, p21, and p27 in bone marrow LSK stem/progenitor cells
after each round of transplantation. This revealed a significant
compensatory upregulation of p18 and p27 transcripts and
protein, but not of p21. To study whether this compensatory
upregulation is functionally significant, Zou and colleagues per-
formed shRNA-mediated knockdown of p57 on a p27 mutant
background, and also analyzed mice transplanted with FL
HSCs derived from p57/p27 double mutant mice. In both cases,
the reconstitution capacity was significantly reduced after serial
transplantation. In this setting the phenotype was associated
with a decrease in HSC quiescence while progenitor proliferation
was unaffected. These data strongly suggest that the compen-
satory upregulation of p27 in p57-deficient FL HSCs preserves
their quiescence and most of their functional capacity. Although
both studies demonstrate the relevance of p57 in HSC mainte-
nance, the phenotypes are not absolute, as self-renewal and
reconstitution activity are still present (albeit drastically reduced)
in cells lacking both p57 and p27.
Does p57 Maintain Quiescence, or Is It Important
for Entering Quiescence?
Do the genetic data really address whether p57 is necessary for
the maintenance of dormant/quiescent HSCs, or do the experi-
ments show that p57 upregulation is a critical mechanism to
establish quiescence of initially cycling HSCs? Evidence for the
latter comes from the fact that Zou and colleagues study FL
HSCs that are inherently cycling, and only achieve quiescence
later on in the adult in specialized niches of the bone marrow.
Similarly, the conditional knockout (KO) approach used by
Matsumoto and colleagues induces Cre-mediated deletion of
the p57 gene by pIC, which is known to rapidly activate all
dormant HSCs (Essers et al., 2009). Because activation ofHSCs is likely faster than deletion of p57, the protein is lost in
already-cycling HSCs. Thus, in both cases, the data show that
p57 is important for the establishment of quiescence starting
from cycling HSCs. Future experiments using other inducible
Cre systems that do not activate HSCs, such as the SCL-
CreERT2 allele, will be necessary to address whether p57 is
critical to maintain quiescence of HSCs in vivo. Nevertheless,
the data show that failure of HSCs to enter quiescence is asso-
ciated with decreased self-renewal (Matsumoto et al., 2011; Zou
et al., 2011). Moreover, it is interesting to observe that condi-
tional ablation of p57 produced a more profound phenotype
than that observed in straight KO mice. Whereas this pattern
might be explained by compensatory mechanisms that become
active in germline KOmice, it also raises the question of whether
conditional approaches targeting the other CDKi family mem-
bers will reveal more severe phenotypes as compared with the
reported germline KO models.
p18 and p27: Two Collaborators of p57
In both studies, p57-deficient HSCs compensatorily upregulated
p18 and p27 (Figure 1B). Although p27 protein is expressed in
normal HSCs, it is not differentially regulated within the various
HSC and progenitor populations (Figure 1B) (Yamazaki et al.,
2006; Matsumoto et al., 2011; Zou et al., 2011). Genetic defi-
ciency of p27 affects mostly progenitor cells, resulting in their
increased number and cycling. Moreover, progenitor cells lack-
ing p27 outcompete their wild-type counterparts in serial and
competitive transplantation, and they enhance survival of mice
in short-term radioprotection assays. However, lack of p27
does not perturb HSC number, cycling, or repopulation potential
(Cheng et al., 2000). Thus, p27 negatively regulates the hemato-
poietic progenitor pool without playing a specific major role in
HSC function. However, it may be important for fine-tuning the
cell cycle of HSCs, because p27 interacts not only with p57,
but also with the Myc-Max-Mad transcription factors, and
p27/Mad1 double mutants display increased HSC number
(Walkley et al., 2005).
The second CDKi upregulated in p57 mutant HSCs was p18,
which has previously been shown to regulate HSC function.
Mice deficient for p18 displayed an expansion of stem and
progenitor cells, which showed a competitive advantage in serial
bone marrow transplantation assays compared with that of
normal controls (Yu et al., 2006; Yuan et al., 2004). This was
associated with an unexpected increase in HSC cycling,
because typically, increased HSC cycling is almost always asso-
ciated with stem cell exhaustion in serial transplant settings. As a
mechanism for this novel phenotype, it has been proposed
that p18 mutant HSCs have a shorter G1 phase due to a lower
cyclinD/CDK4 threshold activity. According to this model,
mutant cells transit more rapidly through late G1, and thus would
be less exposed to differentiation-inducing cytokine stimuli, re-
sulting in increased self-renewal capacity (Orford and Scadden,
2008). Hence, p18 appears to be a CDKi that balances HSC self-
renewal and differentiation by regulating the kinetics of early G1
transit. Because p57-controlled exit from G0 and p18-controlled
G1 length are consecutive biological processes, it is likely that
p18 and p57 function are highly coordinated or possibly even
dependent on each other. Future genetic studies analyzing the
phenotype of p57/p18 double mutant HSCs will likely provideCell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc. 189
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dormancy and self-renewing divisions in functional HSCs.
The Role of Other CDKIs in Control of HSC Function
Although p21CIP1 (p21) was initially indicated to be an important
regulator of normal HSC function, more recent data suggest that
the role of p21 is mainly restricted to genotoxically stressed
HSCs (Choudhury et al., 2007; van Os et al., 2007; Viale et al.,
2009). Unlike other members of the CDKi families, p21 is a p53
target gene and is a key mediator of p53-mediated G1 arrest
and apoptosis (el-Deiry et al., 1994). In response to DNA damage
provoked by telomerase dysfunction, CD34-KLS HSCs were
shown to upregulate p21, detrimentally affecting their function.
In this setting, HSC self-renewal was rescued by p21 deletion
(Choudhury et al., 2007). Intriguingly, while p21 impairs normal
HSC self-renewal during the DNA damage response induced
by telomerase dysfunction, it maintains leukemic stem cell
self-renewal during oncogene-induced DNA damage. In a PML-
RAR leukemia model, it was shown that p21 prevents leukemic
stem cell exhaustion by limiting cell proliferation and accumula-
tion of DNA damage (Viale et al., 2009).
p16INK4a mRNA levels are high in primitive CD34-LSK HSCs
and progressively decrease during progenitor commitment
(Figure 1B) (Passegue´ et al., 2005). Interestingly, increased p16
expression has been observed in aged HSCs or in response to
stress such as reactive oxygen production (Ito et al., 2004; Jan-
zen et al., 2006). Consistently, p16 plays amajor role in regulating
HSC function during aging. In young mice p16 deficiency is
dispensable for HSC self-renewal (Stepanova and Sorrentino,
2005). However, in old mice, lack of p16 increased the number
of long-term HSCs. Moreover, in serial transplantation assays,
p16-deficient old HSCs showed increased cell cycle entry and
outcompeted p16-deficient young HSCs (Janzen et al., 2006).
Furthermore, activation of the p16-CDK4/CDK6-Rb signaling
pathway has been shown to be involved in defective stem cell
maintenance in response to intracellular reactive oxygen species
(ROS) elevation, a situation associated with aging (Ito et al.,
2004). In summary, p16 plays a major role in the age-related
decline of HSC function.
p57 and Hsc70 Control HSC Quiescence by Shuttling
CyclinD to the Nucleus
At the molecular level, Zou et al. showed that HSCs lacking p57
and p27 had increased Rb phosphorylation. To address the
mechanism behind this phenomenon, the authors analyzed the
expression of the various cell cycle components by immunoflu-
orescence of FACS-sorted HSCs. This revealed a surprising
finding: p57 and cyclinD1 are localized to the cytoplasm of un-
stimulated HSCs, while the CDKs are all localized to the nucleus.
In response to stimulation by stem cell factor (SCF), p57 is
degraded, expression of CDKs increased, cyclinD1 moves to
the nucleus, and Rb becomes phosphorylated (Zou et al.,
2011). These data suggest that in HSCs, p57 might not inhibit
nuclear cyclinD/CDK complexes directly, but rather, indirectly,
by retaining cyclinD1 in the cytoplasm.
To shed light on this observation, Zou et al. used a coimmuno-
precipitation approach to identify proteins that were bound to
Myc-tagged p57 in the hematopoietic progenitor cell line EML.
Unexpectedly, Hsc70, a member of the heat shock protein 70190 Cell Stem Cell 9, September 2, 2011 ª2011 Elsevier Inc.(HSP70) family, immunoprecipitated with p57. This molecular
chaperone is known as a factor that shuttles proteins from the
cytoplasm to the nucleus, and is also known to bind cyclinD1.
Subsequent binding studies revealed that p57 and p27 formed
complexes with Hsc70 in the cytoplasm, possibly retaining a
cyclinD1-Hsc70 complex in this compartment, thus preventing
G1 cell cycle progression via Rb phosphorylation. To show
that Hsc70-mediated retention of cyclinD1 is a key mechanism
in preserving cell quiescence, Hsc70 or an Hsc70 mutant that
lacked the nuclear localization-related signal (NLRS) was trans-
duced into LSK stem/progenitors and transplanted into lethally
irradiated mice. HSCs overexpressing Hsc70 showed an in-
crease in proliferation and a decrease in quiescence and were
less able to form colonies in vitro. These effects were blunted
in HSCs overexpressing the mutant form of Hsc70 that is unable
to shuttle cyclinD1 to the nucleus.
The ability of both p57 and p27 to interact with Hsc70might be
themolecular basis for the functional overlap of these CDKis that
includes the p27 compensatory role in the absence of p57.
However, the exact biochemical composition of the complexes
that bring Hsc70-cyclinD1 together with p27 and p57 remains
unclear. Several scenarios are plausible. First, a quaternary
complex where both p27 and p57 are bound to Hsc70-cyclinD1
might exist. Alternatively, Hsc70-cyclinD1 may only bind either
p27 or p57, resulting in two distinct complexes (p57-Hsc70-
cyclinD1 and p27-Hsc70-cyclinD1). In a third possibility, the
p57-Hsc70-cyclinD1 complex would be the predominant
complex in quiescent HSCs, while finally p27 is only part of the
complex in the absence of p57 (Figure 2). Future biochemical
studies will need to determine the stochiometric relationships
between the various complexes and their roles in cell cycle
activation.
Concluding Comments
In summary, the data predict a model in which niche-secreted
quiescence-inducing growth factors such as TPO and TGF-beta
induce and maintain the expression of cytoplasmic p57. This
factor forms a complex with Hsc70-cyclinD1 and prevents
cyclinD1 from entering the nucleus and activating Rb-mediated
G1 progression (Figure 2). Activating cytokines such as SCF or
IFNa (interferon-alpha) are likely associated with an exit of
HSCs from the niche environment that maintains HSC quies-
cence. This move leads to the transcriptional downregulation
and degradation of p57. CyclinD1 enters the nucleus via Hsc70
and activates CDK4/6 complexes, which in turn phosphorylate
Rb. Subsequently, hyperphosphorylation of this transcription
factor by cyclinE/CDK2 promotes E2F activation and initiation
of the S phase program. The identification of Hsc70-cyclinD1-
mediated regulation of cell cycle entry of quiescent HSCs is
novel and fascinating. It will be interesting to see whether this
is a mechanism also used in other types of dormant stem cells
such as those present in the brain or bulge region of the skin
epidermis, and whether this is a general mechanism to exit
from a deeply quiescent G0 stage. The roles played by the
classic nuclear inhibitory mechanisms of CDKIs in HSCs still
remain to be explored. While p57 seems to function predomi-
nantly in the cytoplasm by preventing cyclinD1 shuttling in the
nucleus, other CDKis such as p18 are strictly nuclear and thus
potentially inhibit CDKs in that compartment via mechanisms
Figure 2. Model for the Role of p57 in HSC Quiescence
Left: In wild-typemice, TPO and TGF-beta signaling induces p57 expression. p57 establishes an interactionwith cyclinD-Hsc70 in a quaternary complex with p27
(A), by competing with p27 for cyclinD-Hsc70 binding (B), or independently of p27 (C). The presence of p57 prevents cyclinD from entering the nucleus. This
prevents CDK activation and Rb phosphorylation, thus preserving HSC quiescence. Middle: In the genetic absence of p57 and/or p27, Hsc70 promotes the
nuclear import of cyclinD1. CyclinD1 then complexes with CDK4/6, which phosphorylate Rb on Ser608 and Ser780. Rb phosphorylation in turn promotes entry
into G1 phase, thus leading to exit from quiescence and entry into the cell division cycle. Right: Activating cytokines such as SCF or interferons (INFs) inhibit p57,
thus eliciting a self-renewal division by the signaling pathway described in the middle panel.
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in a concerted manner by nuclear and cytoplasmic CDKis acting
via distinct cellular and molecular pathways.
This new data on p57 and HSC quiescence are of major sig-
nificance, because cell cycle quiescence and dormancy is one
of the mechanisms that allow cancer stem cells to escape
antiproliferative chemotherapy and to possibly mediate resis-
tance to targeted therapies such as imatinib in BCR-Abl driven
CML. Along these lines, the identification of Hsc70 may allow
the design of novel therapeutic strategies to drive cells out of
quiescence into a more drug-sensitive stage. Indeed, Hsc70 is
upregulated in imatinib-resistant CML and pharmaceutical inhi-
bition of this protein has already been shown to decrease the
survival of CML cells in combination with imatinib (Jose´-Ene´riz
et al., 2008). Future approaches will need to uncover further
players in the machinery that links quiescence and self-renewal
activity in normal and leukemic stem cells to allow the develop-
ment of more efficient strategies to target the entire pool of
leukemic stem cells within a patient.
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